POLYCYSTIC OVARY SYNDROME: HETEROGENEOUS PHENOTYPES, ENDOCRINE DYSFUNCTION, AND LONG-TERM CLINICAL IMPLICATIONS
DOI:
https://doi.org/10.63330/aurumpub.024-040Keywords:
Polycystic Ovary Syndrome, Hyperandrogenism, Ovulatory Dysfunction, Insulin Resistance, Clinical PhenotypesAbstract
In PCOS, there is increased LH secretion and decreased FSH secretion. Therefore, there is an increase in androgen production and a decrease in estrogen production in the ovaries, leading to the hyperandrogenism characteristic of PCOS. Subsequent alterations occur due to disturbances in the negative feedback of these hormones on the HPO axis, leading to loss of cyclicity and chronic anovulation. In PCOS, there is an increase in LH and a decrease in FSH. FSH is the follicle-stimulating hormone. That is, there is a decrease in the stimulus for the development of follicles, which remain stagnant and do not fully develop. Thus, ovulation does not occur. Therefore, the ovaries become full of immature follicles and become polycystic.
Downloads
References
1. Teede HJ, Misso ML, Costello MF, et al. Polycystic ovary syndrome in 2025 — insights and innovations. Journal of Clinical Endocrinology C Metabolism, 2025. Disponível em: PubMed.
2. Azziz R, Carmina E, Chen Z, et al. Polycystic ovarian syndrome: a comprehensive review of pathophysiology, diagnosis, and management. International Journal of Molecular Sciences, v.23, n.2, p.583, 2022.
3. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with PCOS. Fertility and Sterility, 2005. DOI:10.1016/j.fertnstert.2005.01.121.
4. Legro RS, Arslanian AS, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: na Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology C Metabolism, 2013. (Revisão clínica amplamente citada).
5. Bjorn Jensen et al. Long-term health outcomes in polycystic ovary syndrome. Steroids, 2024. (Narrative review sobre prognóstico metabólico e cardiovascular).
6. Wild RA, Rizzo M, Clifton S, et al. Polycystic ovary syndrome and the risk of cardiometabolic disease: longitudinal evidence. Diabetes/Metabolism Research and Reviews, 2018;34(10):e3054.
7. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: na update on mechanisms and implications. Endocrine Reviews, v.33, n.6, p.981-1030, 2012.
8. Palomba S, Falbo A, Orio F Jr. Evidence-based and emerging clinical treatments for women with PCOS. Endocrine, v.43, p.428-441, 2013. (Revisão terapêutica).
9. Jones GL, Hall JM, Balen AH, et al. Lifestyle and pharmacological interventions for improving insulin resistance in PCOS women: systematic review and meta-analysis. Human Reproduction, 2019.
10. IB Rodriguez, S Gupta, et al. Impact of subclinical hypothyroidism on endocrine features in patients with polycystic ovary syndrome. European Journal of Medical Research, v.30, p.725, 2025.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
